Order Article Reprints

Wu S, Edwards H, Wang D, Liu S, Qiao X, Carter J, Wang Y, Taub JW, Wang G, Ge Y. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Cells. 2022; 11(17):2752. https://doi.org/10.3390/cells11172752

Wu, Shuangshuang, Holly Edwards, Deying Wang, Shuang Liu, Xinan Qiao, Jenna Carter, Yue Wang, Jeffrey W. Taub, Guan Wang, and Yubin Ge. 2022. "Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia" Cells 11, no. 17: 2752. https://doi.org/10.3390/cells11172752

Wu, S., Edwards, H., Wang, D., Liu, S., Qiao, X., Carter, J., Wang, Y., Taub, J. W., Wang, G., & Ge, Y. (2022). Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Cells, 11(17), 2752. https://doi.org/10.3390/cells11172752